Morgan Stanley analyst Sarita Kapila upgraded Roche (RHHBY) to Equal Weight from Underweight with an unchanged price target of CHF 295. The firm says the company’s recent pipeline setbacks now look better reflected in the stock’s valuation. 2026 is an execution year for Roche, with limited upside catalysts before 2027, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche reports Q1 group sales CHF 14.7B vs. CHF 15.4B last year
- Roche expects increase in group sales in mid single digit range for FY26
- Genentech’s treatment of KRAS G12C-positive NSCLC granted FDA orphan designation
- Genetech says Phase III METEROID study of Enspryng meets primary endpoint
- Roche announces U.S. FDA accepted sBLA for Gazyva/Gazyvaro